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Abstract: It is unclear whether patients with non-celiac gluten sensitivity (NCGS) can tolerate
gluten. We have evaluated the changes of both gastrointestinal symptoms and quality of life for
NCGS patients after the re-introduction of dietary gluten. Twenty-two NCGS patients reporting
functional gastroenterological symptoms and on gluten-free diet (GFD) for the previous three weeks
were exposed to incremental gluten-containing diets. Three groups were compared at baseline
(immediately after 3-weeks on GFD) and immediately after the return of symptomatology: (i) a group
tolerating a low-gluten diet (3.5 g gluten/day, week 1, n = 8), (ii) a group tolerating a mid-gluten diet
(8 g gluten/day, week 2, n = 6), and (iii) a group tolerating a high-gluten diet (13 g gluten/day,
week 3, n = 8). Their gastrointestinal symptoms and quality of life were assessed at baseline
and post-intervention. The most common symptoms were: constipation (46%), abdominal pain
(50%) and dyspepsia (38%). A decrease in several short form health survey (SF-36) sub-scores
(all p < 0.03) after gluten re-introduction was only observed in the group tolerating the low-gluten
diet; the same group showed a lower post-intervention role-emotional SF-36 score (p = 0.01). Most
gastrointestinal symptoms remained similar after gluten re-introduction. However, a decrease in the
general perception of well-being was only found after gluten re-introduction in the group tolerating a
low-gluten diet (p = 0.01); the same was true when comparing the post-intervention general well-being
perception among the three groups (p = 0.050). In conclusion, dissimilar responses from patients
with NCGS were observed after the re-introduction of gluten, with gluten at a low dosage affecting
the quality of life and general well-being of a group of patients, whereas others tolerate even higher
doses of dietary gluten.
Keywords: non-celiac gluten sensitivity; gluten re-introduction; gluten-free diet; gastrointestinal
symptoms
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1. Introduction
Non-celiac gluten sensitivity (NCGS) is characterized by intestinal and extra-intestinal symptoms
related to the ingestion of gluten-containing foods, in subjects that are not affected by either celiac
disease (CD) or wheat allergy [1–3]. The symptomatology commonly found in NCGS comprises:
bloating, abdominal pain, diarrhea, epigastric pain, nausea, aerophagia, lack of well-being, tiredness,
headache, foggy mind, and anxiety among other symptoms [4]. Symptoms disappear after starting
on a gluten-free diet (GFD) and appear again after a gluten challenge within a few hours or a couple
of days [5,6]. However, this latter finding can be attributed to a placebo/nocebo effect [7,8]. Several
studies have evaluated the effect of a gluten re-challenge in NCGS patients after GFD (a summary of
studies is shown in Table 1). According to a recent meta-analysis, there is a wide range of patients
relapsing after a gluten challenge (between 7% and 77%) and no effect of a gluten challenge was found
on the risk of relapse [9]. These results are in line with another review of studies on patients with
suspected NCGS, indicating that only 16% of them show clear gluten-specific symptoms [10]. These
studies highlight the fact that further methodological considerations are required in studies evaluating
the gluten challenge.
The current clinical consensus is that the diagnostic criteria on NCGS should include self-reported
gluten intolerance, negative serology for CD (including immunoglobulin A (IgA) endomysial
antibodies, IgA tissue transglutaminase antibodies, and IgG de-amidated gliadin peptide antibodies)
and the absence of villous atrophy at duodenal histology (whilst on a gluten-containing diet) [1,3,11].
Similarly to CD and wheat allergy, the cornerstone of NCGS treatment is the withdrawal of
gluten-containing foods. Although considered safe and effective, the lifelong elimination of gluten
from the diet carries psychological and social implications. Patients with CD report about concerns
related to the management of their social relationships and life routine [12]. Support and education
are important to enable patients to adapt to their new diet [13]. However, given the uncertainty
on the pathogenesis and trigger(s) of NCGS, it is not clear how strict such a new diet needs to be,
how long its implementation and how to monitor the efficacy of the treatment other than by clinical
response. Clinical experience suggests that patients affected by NCGS range from those who need to
adhere to a strict GFD to those who can tolerate potential cross-contamination without any clinical
consequences [14].
NCGS is a disorder treated with a GFD. There is currently discussion whether the symptoms
described in NCGS are exclusively due to the ingestion of gluten proteins rather than other components
included in wheat [15]. Wheat has some components that are different from gluten proteins and can
be harmful to patients suffering from NCGS, including wheat germ agglutinins (WGA), amylase
inhibitors/trypsin (ATI), and fermentable oligo/di/monosaccharides and polyols (FODMAP) [16–19].
ATIs are a family of structurally similar proteins, which serve as protective proteins in wheat and other
cereals, by inhibiting the enzymes (trypsin and trypsin-like activities) of wheat and some parasites [20]
ATIs have been described as triggers of the activation of innate immunity in intestinal cells [18].
WGAs [19], similar to ATIs, serve as protective proteins as they are resistant to heat and proteolysis.
WGAs have shown to promote the production of pro-inflammatory cytokines, which affect the integrity
of the intestinal epithelium [21]. Finally, FODMAP-containing foods include such components as
oligosaccharides, disaccharides, monosaccharides, and sugar alcohols. They are resistant to digestion
and can ferment completely or partially in the large intestine. Their efficacy in the treatment of
gastrointestinal symptoms related to IBS has been described, and their function is being evaluated in
various pathologies affecting the intestine [22,23].
Nutrients 2019, 11, 136 3 of 14
Table 1. Summary of clinical trials evaluating a gluten re-challenge in NCGS patients.
Study (Reference) Patients Study Design No. of Patients Challenge Duration Methods Main Findings
Biesiekierski et al. [5] NCGS w/IBS DBRPCT 34 patients up to 6 weeks Gluten or placebo (two bread slicesplus one muffin per day)
68% (13) of patients in the gluten group
reported inadequate symptoms control
compared with 40% (6) under placebo.
Carroccio et al. [24] NCGS DBRPCT 2 weeks Capsules with wheat (20 g) vs.placebo
30% (276) of patients diagnosed as
non-celiac wheat sensitivity. Wheat
challenge induced >30% increase in
symptoms.
Peters et al. [25] NCGS w/IBSsymptoms DBRPCT 22 patients 3 days
Dietary challenge: gluten-free food
supplemented with gluten
(16 g/day), whey (16 g/day) or not
supplemented (placebo)
Higher overall Spielberger State Trait
Personality Inventory state depression
scores compared to placebo but not
whey, after gluten. Similar
gastrointestinal symptoms induced after
all treatments
Zanini et al. [26] NCGS DBRPCT 35 non-CDpatients 10 days
Gluten-containing flour or
gluten-free flour for 10 days,
followed by a 2-week
washout period
34% of patients diagnosed as
having NCGS
Capannolo et al. [27] NCGS DBRPCT
364 patients
(27 with NCGS
and 337 with no
specific diagnosis)
1 month Challenge with dietary gluten vs.a GFD.
85.96% did not experience a change in
symptomatology after a GFD. Low
value of a gluten-containing diet for an
increase in symptoms.
Rosinach et al. [28] NCGS DBRPCT 18 non-CDpatients 6 months 11 gluten (20 g/day) and 7 placeboes
91% of patients with clinical relapse
during gluten challenge (vs. 28.5%
after placebo)
Picarelli et al. [29] NCGS DBRPCT 26 patients 1 day
Food challenge (oral provocation test)
with a gluten-containing croissant
(10 g of gluten per croissant) to
13 patients and a gluten-free croissant
to the other 13 patients.
No difference was found between the
severity of symptoms with
gluten-containing croissants compared
to a group of patients with
gluten-free croissants.
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Table 1. Cont.
Study (Reference) Patients Study Design No. of Patients Challenge Duration Methods Main Findings
Elli et al. [30]
NCGS
w/functional
gastrointestinal
symptoms
DBRPCT 98 patients 7 days Gluten intake (5.6 g/day) or placebo 28 patients reported symptomaticrelapse with deteriorated quality of life
Skodje et al. [31]
Subjects with
self-reported
NCGS
DBRPCT 59 subjects 7 days Diets containing gluten (5.7 g),fructans (2.1 g), or placebo
Overall Gastrointestinal Symptom
Rating Scale for Irritable Bowel
Syndrome scores increased after
fructans rather than gluten.
Dale et al. [32]
Patients
w/suspected
NCGS
DBRPCT 20 patients 4 days
Two muffins a day (11/0 g gluten).
(4 periods w/double-blinded
provocation, 2 w/gluten,
2 w/placebo)
Most severe symptoms found after
placebo. Only 4/20 patients correctly
identified periods w/gluten.
NCGS: Non-celiac gluten sensitivity; DBRPCT: Double-blind randomized placebo-controlled trial; IBS: Irritable bowel syndrome; CD: Celiac disease; GFD: Gluten-free diet.
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There is currently no data that can support any recommendations on the need for, or frequency of,
repeated follow-up visits in these patients. It is considered good clinical care to study these patients at
regular intervals in order to ensure they remain healthy and to involve a nutritionist to make sure they
are not at risk of nutrient deficiencies. It is also advisable that the continued need for “strict” avoidance
of all gluten-related products be regularly reviewed following recovery because some patients can
possibly follow a less restrictive diet with no recurrence of symptoms. A lifelong strict GFD (as in CD)
vs. an “on-demand” approach is the main question. Many experts recommend that patients should
undergo periodic re-evaluation with the re-introduction of gluten (e.g., every 6–12 months) [8].
A GFD leads to the complete disappearance of symptoms in most patients with NCGS but in
some cases the level of improvement after gluten withdrawal is only partial. However, it should be
mentioned that the level of tolerance varies among individuals and there are patients with NCGS
who do not tolerate even very small amounts of gluten. As it is presently unclear whether gluten
sensitivity is a permanent or transient condition, the re-introduction of gluten after 1–2 years on a
GFD is potentially advisable [33]. Thus, the aim of the present study was to evaluate the changes in
gastrointestinal symptoms and quality of life for NCGS patients after exposure to different amounts of
dietary gluten.
2. Materials and Methods
Between 2013 and 2014, patients reporting functional gastroenterological symptoms according
to the Rome III criteria [34] were invited to participate in this study. All were recruited from the
gastroenterological outpatient clinic at the Center for Prevention and Diagnosis of Celiac Disease,
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
in Milan (Italy). The patients who agreed to participate gave their written informed consent and were
enrolled in the study. The local Ethics Committee for Human Research of the City of Milan approved
the study protocol. The trial was registered in ClinicalTrial.gov (NCT01864993).
The inclusion criteria were: adult age (>18 years old), being on a gluten-containing diet, with
negative anti-tissue transglutaminase IgA, normal IgA dosage, negative IgE-mediated wheat allergy
as verified by skin prick test and serological IgE dosage. The exclusion criteria were: diagnosis of
CD, wheat allergy, inflammatory bowel disease, psychiatric disorders, major abdominal surgery
(in particular, intestinal resections), diabetes mellitus, systemic autoimmune diseases, previous
anaphylactic episodes, any systemic disorders, patients already following or having followed a
GFD regimen in the previous six months, pregnant or breastfeeding women, and patients already
on pharmacological therapy. The patients were evaluated by a gastroenterologist and a qualified
nutritionist. The diagnosis of NCGS was made in accordance with the latest NCGS consensus [4].
After recruitment, patients were requested to follow a GFD plan for 3-weeks before the start of
the dietary intervention (i.e., the low/mid/high-gluten diet). Their overall health, gastrointestinal
symptoms, and quality of life were assessed by medical examination. Their adherence to the GFD was
evaluated according to the celiac dietary adherence test (CDAT) [35]. The CDAT is a clinically relevant,
easily administrated 7-item instrument which allows the standardized evaluation of GFD adherence.
It is a sensitive tool developed using standard psychometric techniques. Only those patients with
excellent or very good GFD adherence were included in the study. CDAT is based on a score ranging
from 7 to 35 against seven questions, each on a 5-point scale, with higher scores denoting worse GFD
adherence [35].
2.1. Intervention
Twenty-four patients were recruited (Figure 1). As mentioned above, all the recruited patients
were instructed to follow a strict GFD for 3 weeks. After that time, the intervention period started.
A qualified nutritionist designed a personalized GFD adjusted to match daily requirements for energy,
macronutrients and micronutrients. A structured 3-week dietary plan was indicated and explained
to every patient, to cover structured meals, foods/beverages and alternatives for food purchase.
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The patients were also encouraged to immediately contact the nutritionist by phone in case of any
doubt related to the diet. After the three weeks on the GFD, the intervention period started. The patients
started the study with a low-gluten diet during the first week (3.5–4 g gluten/day, week 1, n = 24).
Two patients dropped out of the study during the first week because they did not want to continue the
diet. Afterwards, the patients who did not report adverse symptoms were administered a mid-gluten
diet in the second week (6.7–8 g gluten/day, week 2, n = 14). Then, the patients who passed the second
week were started on a high-gluten diet for the following week (10–13 g gluten/day, week 3, n = 8).
Each patient had been instructed to immediately contact the research team at the end of each week
should any of the previously reported symptoms at the beginning of the study return. A clinical
evaluation was then arranged and the patient was to stop their gluten-containing diet and return to
the GFD (i.e., for patients reporting adverse symptomatology at the end of the first week) or to the
previous gluten-containing diet (i.e., for patients reporting adverse symptomatology at the end of the
second and third week). In such cases, the nutritionist would also reinforce the instructions and food
education on the practice of the GFD. A flow-chart of patients is shown in Figure 1. The patients with
symptomatic relapse at the end of week 1 returned to the GFD (as indicated in the previous three
weeks after recruitment). The patients who experienced a symptomatic relapse at the end of week
2 returned to a low-gluten diet (3.5–4 g/day) and stayed on that dietary treatment until the end of
week 3. Finally, none of the patients who had undergone the high-gluten diet (n = 8) reported any
worsening of gastrointestinal symptoms and at the end of week 3, they were instructed to return to
their regular dietary pattern.
2.2. Diets
The nutritional evaluation aimed to assess anthropometrical parameters, nutritional status, and
usual dietary patterns. At the beginning of the study, after clinical evaluation, a structured 7-day
dietary plan was generated for each patient, adjusted to his/her daily nutritional requirements for
energy, macronutrients and micronutrients. For each week, according to the low/mid/high-gluten
amount contained, meals were listed (breakfast, morning snack, lunch, afternoon snack, dinner and
other snacks during the day) with specific foods/beverages (see examples in Table 2). For week
1 the source of gluten was only wheat pasta (50 g, about 3.5–4 g of gluten) administered during
dinner. In week 2 the sources of gluten were wheat pasta (50 g, about 3.5–4 g of gluten) during
dinner and wheat bread (50 g, about 3.2–4 g gluten) during the daytime. For week 3 the sources of
gluten were wheat pasta (60 g at lunch and 60 g at dinner, ~8.4–9.6 g gluten) and wheat bread (30 g
during the day, 1.9–3 g gluten). The gluten content of each of the three diets was calculated referring
to Schalk et al. [36]. In that study, the gluten content was determined through a comprehensive
strategy to isolate gluten protein fractions and gluten protein types (GPT) from wheat, rye, barley, and
oat flours. All of the isolated GPTs were fully characterized by means of analytical reversed-phase
high-performance liquid chromatography (RP-HPLC), sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), N-terminal sequencing, electrospray-ionization quadrupole time-of-flight
mass spectrometry (LC-ESI-QTOF-MS) and untargeted LC-MS/MS of chymotryptic hydrolysates of
the single GPT. Successively, all of the GPTs were reproducibly isolated in high purity from the flours
and were made suitable to be used as a reference material, i.e., for calibration of liquid chromatography
tandem mass spectrometry methods or enzyme-linked immunosorbent assays (ELISAs) [36].
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Table 2. Example of the three dietary plans used and differing in the amount of gluten contained 1.
Meal Low-Gluten(3.5–4 g Gluten)
Mid-Gluten
(6.7–8 g Gluten)
High-Gluten
(10–13 g Gluten)
Breakfast
1 small cup of coffee, 300
mL partly skimmed milk,
1 gluten-free croissant
1 small cup of coffee, 300
mL partly skimmed milk,
4 gluten-free biscuits
1 small cup of coffee, 300
mL partly skimmed milk,
4 gluten-free rusks
Morning snack 1 kiwifruit 1 apple 1 banana
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Table 2. Cont.
Meal Low-Gluten(3.5–4 g Gluten)
Mid-Gluten
(6.7–8 g Gluten)
High-Gluten
(10–13 g Gluten)
Lunch
100 g gluten-free pasta,
90 g mixed vegetables,
1 portion of chard,
4 mandarins
100 g gluten-free pasta,
40 g cow ricotta cheese,
100 g potatoes, 2 bananas
60 g wheat pasta with
broccoli, 2 teaspoonfuls
grated Parmesan cheese,
1 portion of mixed salad,
2.5 glasses of fruit salad
Afternoon snack 1 bowl of strawberries 1 bowl of strawberries 1 pear
Dinner
50 g wheat pasta with
zucchini, 100 g turkey
thigh 200 g potatoes,
5 slices of pineapple
50 g wheat pasta with
tomato sauce, 1 spoon of
fresh peas 120 g pork,
1 portion of chard
5 mandarins
60 g wheat pasta with
tomato sauce, 100 g
halibut, 200 g potatoes,
2 glasses of fruit salad
During the day
40 g gluten-free bread,
6.5 teaspoonfuls virgin
olive oil
50 g of white wheat
bread, 3.5 teaspoonfuls
virgin olive oil
30 g white wheat bread,
8 teaspoonfuls virgin
olive oil
1 Example of a typical day per week for each of the three different diets, as calculated for an average 2000 Kcal/day
energy requirement.
2.3. Gastrointestinal Symptoms and Quality of Life
The gastrointestinal symptoms and quality of life of each patient were assessed at the beginning
of the study and soon after the return of symptoms after administering one of the gluten-containing
diets (i.e., after gluten exposure). A visual analogue scale (VAS) was used to assess the patient’s
gastrointestinal symptoms and general perception of well-being as previously described by our
group [23]. This instrument recorded the severity of specific symptoms: abdominal pain, bloating,
postprandial fullness, early satiety, epigastric pain, non-specific functional gastrointestinal symptoms,
and satisfaction with stool consistency. For each question, each patient was asked to put a mark
along a 10-cm long line with one end 0 meaning “absence of symptom” and the other end 10
“severe symptomatology”. A further VAS evaluated the satisfaction about the current level of general
well-being, with 0 meaning “completely unsatisfied” and 10 “absolutely satisfied”.
The patient’s quality of life was evaluated through the short form health survey (SF-36)
questionnaire. This instrument comprises 36 questions that conceptually refer to eight health
domains [37]. The patients were asked to answer each question and then domain-specific scores
ranging between 0 and 100 were calculated, where 100 represented the best possible perception of
quality of life.
2.4. Statistical Analysis
The data are provided as mean ± SEM or median (interquartile range) unless indicated otherwise.
Twenty-two patients were included for analysis. Comparisons were made according to the group
of patients that reported the return of symptomatology after gluten exposure, that is 3 groups:
low-gluten (patients that reported adverse symptomatology after 1 week on a gluten-containing
diet, n = 8), mid-gluten (patients that reported adverse symptomatology after 2 weeks on a
gluten-containing diet, n = 6), and high-gluten (patients that reported adverse symptomatology after
3 weeks on a gluten-containing diet, n = 8). One-way ANOVA was used to evaluate between-group
differences as to age and body-mass index; Fisher’s exact test was used to compare categorical
variables (i.e., gender distribution and presence of gastrointestinal symptoms) between the groups.
The within-group differences of SF-36 and VAS scores before (immediately after 3-weeks on a GFD)
and after gluten exposure (i.e., baseline vs. the time when gastrointestinal symptoms returned
after the gluten-containing diets) were assessed using a non-parametric Wilcoxon’s rank sum test.
The between-group differences were evaluated after gluten exposure using the non-parametric
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Kruskal-Wallis test. STATA® ver. 13.1 software (StataCorp, College Station, TX, USA) was used
for statistics and statistical significance was set at a 5% α-level.
3. Results
3.1. Patients
All patients included in the study obtained a CDAT score from 7 to 13, thus indicating very
good adherence to the GFD. As shown in Table 3, the patients were middle-aged, mainly women,
and within the normal weight range. Regarding the clinical symptomatology at baseline, symptoms
such as constipation, abdominal pain, and dyspepsia were the most frequently reported by the whole
sample (46%, 50%, and 38%, respectively). All three groups were comparable regarding both general
characteristics and present gastrointestinal symptoms at baseline (Table 3). In regards to the estimated
gluten content in the foods used in the intervention diets, the gluten content was 3.5–4 g/day in the
low-gluten diet, 6.7–8 g/day in the mid-gluten diet, and 10–13 g/day in the high-gluten diet.
Table 3. General characteristics of the group of patients at baseline 1.
Low-Gluten
(3.5–4 g/day, n = 8)
Mid-Gluten
(6.7–8 g/day, n = 6)
High-Gluten
(10–13 g/day, n = 8) p-Value
†
Age, years 44.6 ± 4.5 45.5 ± 3.1 44.6 ± 5.2 0.98
Gender, F/M 7/1 6/0 7/1 0.99
BMI, kg/m2 23.0 ± 1.7 23.8 ± 1.8 21.8 ± 0.7 0.65
Diarrhea, n (%) 1 (12.5) 0 (0) 1 (12.5) 0.99
Bloating, n (%) 0 (0) 2 (33.3) 1 (12.5) 0.24
Constipation, n (%) 3 (37.5) 5 (83.3) 3 (37.5) 0.21
Abdominal pain, n (%) 5 (62.5) 4 (66.6) 3 (37.5) 0.64
Dyspepsia, n (%) 6 (75) 1 (16.6) 2 (25) 0.08
1 Data are shown as mean ± SEM for continuous variables and frequency and/or relative number for nominal
variables. † p-value for comparison between groups using one-way ANOVA or Fisher’s exact test for categorical
variables. F: female; M: male; BMI: body mass index.
3.2. Quality of Life
The resulting SF-36 scores are shown in Table 4. There was a significant decrease in several SF-36
sub-scores (role physical, role emotional, bodily pain, mental health, vitality and social interaction,
all p < 0.03) after gluten exposure in the group of patients receiving the low-gluten diet but not in
the groups receiving mid- and high-gluten content (Table 4). However, when comparing the change
in SF-36 scores after dietary gluten exposure between the three groups, we observed a change only
in the role emotional score, which was lower in the low-gluten content group. No post-intervention
differences were found regarding the general health score among the three groups (Table 4).
3.3. Gastrointestinal Symptoms
The within-group comparisons showed no significant changes in most of the evaluated
gastrointestinal symptoms before and after dietary intervention (Table 5). However, a decrease
in the general perception of well-being was found in the low-gluten group (but not in the mid- and
high-gluten groups) after intervention (p = 0.01). In line, when comparing the three groups after dietary
gluten exposure, a further decrease of the general well-being level was found in the low-gluten group
compared with the mid- and high-gluten groups (p = 0.050, Table 5).
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Table 4. SF-36 subscales and global score for quality of life 1.
Low-Gluten
(3.5–4 g/day, n = 8)
Mid-Gluten
(6.7–8 g/day, n = 6)
High-Gluten
(10–13 g/day, n = 8)
Baseline 7-Day p-Value † Baseline 14-Day p-Value † Baseline 21-Day p-Value † p-Value ‡
Physical functioning 100.0 (5.0) 95.0 (10.0) 0.10 100.0 (20.0) 82.5 (45.0) 0.17 100.0 (2.5) 100.0 (2.5) 0.94 0.13
Role physical 100.0 (25.0) 50.0 (37.5) 0.03 87.5 (25.0) 100.0 (50.0) 0.72 87.5 (37.5) 87.5 (62.5) 0.65 0.19
Role emotional 79.0 (26.0) 41.0 (31.0) 0.004 79.0 (26.0) 62.5 (32.0) 0.92 84.0 (27.5) 67.5 (40.5) 0.83 0.01
Bodily pain 76.0 (22.5) 53.5 (47.5) 0.008 76.0 (22.5) 64.0 (11.0) 0.87 66.5 (50.0) 69.5 (44.0) 0.30 0.15
Mental health 65.0 (20) 47.5 (17.5) 0.12 65.0 (20.0) 55.0 (20.0) 0.74 72.5 (15.0) 57.5 (37.5) 0.79 0.48
Vitality 87.0 (12.5) 56.0 (18.5) 0.02 87.0 (12.5) 62.5 (38.0) 0.50 100.0 (31.5) 68.5 (44.0) 0.34 0.67
Social interaction 100.0 (17.0) 33.0 (33.0) 0.007 100.0 (67.0) 100.0 (34.0) 0.10 100.0 (33.5) 100.0 (17.0) 0.39 0.30
General health 82.0 (18.0) 62.0 (34.0) 0.15 76.0 (20.0) 72.0 (16.0) 0.46 78.0 (10.0) 72.0 (24.0) 0.99 0.49
1 Data are shown as median values (interquartile range); † p-value for comparison within each group (low-, mid- and high-gluten) using a non-parametric Wilcoxon’s rank sum test;
‡ p-value for between-groups comparison (low-, mid-, and high-gluten) post diet using the Kruskal-Wallis test.
Table 5. Visual analogue scale scores for gastrointestinal symptoms 1.
Low-Gluten
(3.5–4 g/day, n = 8)
Mid-Gluten
(6.7–8 g/day, n = 6)
High-Gluten
(10–13 g/day, n = 8)
Baseline 7-Day p-Value † Baseline 14-Day p-Value † Baseline 21-Day p-Value † p-Value ‡
Abdominal pain 0 (1.3) 2.6 (6.1) 0.16 5.3 (4.5) 4.9 (3.6) 0.87 0 (0.4) 0.5 (7.8) 0.22 0.66
Stool satisfaction 3.8 (9.1) 0 (3.4) 0.16 7.0 (9.8) 3.2 (5.4) 0.25 7.6 (8.8) 4.1 (8.8) 0.99 0.21
Abdominal bloating 0 (3.9) 3.0 (8.4) 0.19 5.4 (5.5) 5.2 (6.0) 0.87 0 (2.2) 3.5 (8.8) 0.19 0.68
Postprandial fullness 0 (4.4) 4.3 (7.4) 0.12 0 (6.7) 0 (2.9) 0.84 0 (0.0) 2.5 (6.6) 0.29 0.37
Early satiety feeling 0.2 (1.8) 3.5 (5.2) 0.13 0 (1.0) 0 (1.4) 0.84 0 (0.0) 1.3 (6.4) 0.09 0.36
Epigastric burn 0 (0.9) 2.0 (8.2) 0.07 0 (2.0) 0 (4.4) 0.85 0 (1.9) 0.7 (5.8) 0.41 0.42
General well-being 9.1 (2.9) 2.1 (2.9) 0.01 7.9 (3.1) 5.9 (4.5) 0.14 8.5 (1.9) 5.1 (4.3) 0.21 0.05
1 Data are shown as median values (interquartile range); † p-value for comparison within each group (low-, mid- and high-gluten) using a non-parametric Wilcoxon’s rank sum test.
‡ p-value for between-groups comparison (low-, mid- and high-gluten) post diet using the Kruskal-Wallis test.
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4. Discussion
This study evaluated the effects of a short-term re-introduction of gluten on individuals diagnosed
with NCGS. Our results show that a level of tolerance is present in patients without showing any
adverse signs or gastrointestinal symptoms when consuming gluten. There was a different response
among individuals with NCGS when exposed to different amounts of dietary gluten. A subgroup of
patients had an immediate response with some worsening of their quality of life and general well-being
at a low-gluten dosage, whereas other patients were able to tolerate medium and high doses of gluten,
indicating that these latter groups can be administered some gluten without adverse health effects.
At present, it is well known that a GFD is the treatment of choice for patients suffering from NGCS.
Several randomized controlled trials (RCTs) [10] have been carried out to identify gluten as the trigger
of symptoms (Table 1). Those reports have shown variable results and are not conclusive regarding
the cause-effect relationship of gluten and gastrointestinal symptoms [30,32]. We have previously
suggested that gluten can be a major trigger of gastrointestinal symptoms in line with other [5,38,39].
Although the data to date suggest a benefit from a GFD for a selected group of patients, it is possible
that the improvement in symptoms might not be due to gluten itself. Other components in wheat
may trigger the reported symptoms in these patients, suggesting the clinical feature of non-celiac
wheat sensitivity. This last entity has not completely been clarified as it is not clear whether patients
are suffering from gluten-related symptoms or another component of wheat (such as fructans) [40].
Regardless of the nomenclature, Carroccio et al. [41] provided a clinically useful approach confirming
non-celiac wheat sensitivity as a unique clinical condition. Their results suggest the existence of two
different groups of patients with this condition: one with characteristics similar to CD and the other
with characteristics resembling food allergy [41]. The current nomenclature of gluten sensitivity [1],
NCGS [5] and gluten-related disorders does not resolve this problem and may confuse clinicians as to
which component in wheat might be triggering patients’ symptomatology. Expert recommendations
have proposed a periodic evaluation with re-introduction of gluten for NCGS patients on consideration
of the economic costs and quality of life that a lifelong GFD entails [8].
Regarding the quality-of-life perception, previous data of our group from a cross-over study has
shown that patients with NCGS treated with a GFD enjoy an improvement in the majority of the SF-36
scores after 7 days [30]. In our study, we observed that the group who tolerated only a low amount of
dietary gluten was the only group showing a decrease in several SF-36 sub-scores. On the other hand,
it is important to point out that the groups on a mid- and high-gluten diet did not show any significant
change in their quality of life. This finding is intriguing because it would suggest that a greater gluten
intake by patients with NCGS would not necessarily further affect their quality of life, thus reinforcing
the idea of inter-individual variability against gluten in this group.
After the re-introduction of gluten, the gastrointestinal symptomatology showed no main changes
against our dietary intervention. Moreover, no differences were found after gluten exposure among
the three groups (i.e., at the end of the intervention period). However, we did find a change in the
perception of general well-being, which was significantly affected in the group receiving a low level
of gluten; such a result is in line with what we found on the patients’ quality of life. Overall, these
findings suggest that with regard to quality of life and general well-being the changes observed in
the group on a low-gluten diet would be related to a systemic response to gluten consumption rather
than only gastrointestinal symptomatology or, at least, a combination of both. Even if our results are
interesting per se they require further confirmation in larger samples and with different populations of
patients suffering from NCGS.
This was an exploratory study that worked on a small sample of patients to evaluate the
re-introduction of gluten through dietary modifications in a homogeneous group of patients correctly
diagnosed with NCGS. As to limitations, we would like to point out that all the patients did not receive
all their gluten doses in a balanced cross-over design. This was mainly due to ethical considerations
since, at the time the clinical picture began to worsen, the patients stopped the administered diet and
returned to their established treatment with GFD.
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To summarize, we have shown a dissimilar response after the reintroduction of gluten in patients
with NCGS who were on GFD for the last 3-weeks. We have also shown that for a group of them
the re-introduction of gluten at low dosage affected their quality of life and general well-being,
whereas other patients could tolerate higher doses of dietary gluten. Further studies are needed to
establish whether NCGS patients require a dietary regimen free of gluten or just a gluten-restricted
diet. Therefore, a controlled re-introduction of gluten potentially helps the improvement of selected
patients that are able to tolerate gluten intake by developing a personalized diet containing gluten
without the reappearance of symptoms. Further research is needed to assess the long-term clinical
response of the increase in the dietary gluten content as concerns symptomatology and quality of life
for patients with NCGS.
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